Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18585322 | METHOD FOR PRODUCING PLATELETS | February 2024 | April 2025 | Abandon | 13 | 1 | 0 | No | No |
| 18499655 | LIPOSOME COMPOSITIONS AND METHODS OF USE THEREOF | November 2023 | March 2025 | Abandon | 16 | 1 | 0 | No | No |
| 18372833 | ANTIBODY-EVADING VIRUS VECTORS | September 2023 | March 2024 | Allow | 5 | 1 | 0 | No | No |
| 18083916 | ADVANCED PULMONARY MODELS | December 2022 | April 2025 | Abandon | 28 | 1 | 1 | Yes | No |
| 17808122 | PREPARATION METHOD OF THERMOSENSITIVE GEL FOR TREATING ANDROGENETIC ALOPECIA | June 2022 | May 2025 | Abandon | 35 | 1 | 1 | No | No |
| 17657646 | ANIMAL MODEL, METHODS FOR MAKING AND USING THEREOF, AND COMPOSITION FOR TREATING ATAXIA | April 2022 | May 2024 | Abandon | 26 | 1 | 1 | No | No |
| 17628688 | METHOD FOR PREPARING INDUCED PLURIPOTENT STEM CELL WITHOUT USING HYDROGEL | January 2022 | June 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17595634 | METHODS FOR GENERATION OF TUMOR ORGANOID-FISHED T CELLS AND IDENTIFICATION OF ANTI-TUMOR T CELL RECEPTORS | November 2021 | June 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17455763 | EXPANSION CULTURE METHOD FOR CARTILAGE OR BONE PRECURSOR CELLS | November 2021 | March 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17530345 | METHODS OF MODULATING SEX RATIO | November 2021 | June 2025 | Abandon | 43 | 3 | 1 | No | No |
| 17499036 | PARALLEL AND INTERCONNECTED CELL CULTURE VESSEL SYSTEM | October 2021 | March 2024 | Abandon | 29 | 0 | 1 | No | No |
| 17593859 | POLYNUCLEOTIDE AND USES THEREOF | September 2021 | February 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17406670 | COMPOSITIONS AND METHODS FOR USE OF RED-SHIFTED ANION CHANNEL RHODOPSINS | August 2021 | March 2024 | Abandon | 31 | 1 | 1 | No | No |
| 17401174 | METHODS OF TREATING SENSITIZED PATIENTS WITH HYPOIMMUNOGENIC CELLS, AND ASSOCIATED METHODS AND COMPOSITIONS | August 2021 | October 2024 | Abandon | 38 | 1 | 1 | No | No |
| 17332855 | ADENO-ASSOCIATED VIRUS VIRIONS WITH VARIANT CAPSIDS AND METHODS OF USE THEREOF | May 2021 | February 2024 | Allow | 33 | 1 | 1 | Yes | No |
| 17327562 | GENE THERAPY DELIVERY OF PARKIN MUTANTS HAVING INCREASED ACTIVITY TO TREAT PARKINSON'S DISEASE | May 2021 | June 2024 | Allow | 37 | 2 | 1 | Yes | No |
| 17307117 | MODIFIED ADENO-ASSOCIATED VIRUS 5 CAPSIDS AND USES THEREOF | May 2021 | September 2024 | Allow | 41 | 2 | 1 | Yes | No |
| 17306153 | CELLS ENGINEERED FOR CO-EXPRESSION OF DECOY RECEPTOR 1 AND TNF-RELATED APOPTOSIS-INDUCING LIGAND AND USES THEREFOR | May 2021 | March 2025 | Abandon | 46 | 4 | 1 | No | Yes |
| 17211866 | USE OF CISTANCHE DESERTICOLA POLYSACCHARIDES IN PROMOTING PROLIFERATION AND DIFFERENTIATION OF FEMALE GERMLINE STEM CELLS | March 2021 | July 2023 | Allow | 28 | 1 | 1 | Yes | No |
| 17194424 | USE OF A CAR CELL HAVING CROSSLINKED DISULFIDE BRIDGE ON ANTIGEN RECOGNIZING MOIETY FOR TARGETTING CANCER CELLS | March 2021 | June 2023 | Abandon | 27 | 3 | 1 | Yes | No |
| 17162207 | CELL CULTURE METHOD AND AUTOMATIC CELL CULTURE APPARATUS | January 2021 | December 2023 | Allow | 35 | 2 | 1 | Yes | No |
| 17132784 | 3D STIMULATED TISSUE CONSTRUCTS AND METHODS OF MAKING THEREOF | December 2020 | December 2023 | Abandon | 36 | 2 | 0 | No | No |
| 17127545 | SPHERICAL 3D TUMOR SPHEROID | December 2020 | March 2025 | Abandon | 50 | 4 | 1 | No | No |
| 17053900 | ADJUVANT FOR CELL CULTURE | November 2020 | June 2024 | Abandon | 43 | 0 | 1 | No | No |
| 17077451 | Modified TCR And Uses Thereof | October 2020 | August 2023 | Allow | 34 | 1 | 1 | No | No |
| 17045091 | ANTIBODY-EVADING VIRUS VECTORS | October 2020 | January 2025 | Abandon | 51 | 1 | 1 | No | No |
| 17042763 | STEM CELLS AND PROGENITOR CELLS BEARING CD31 | September 2020 | February 2025 | Abandon | 53 | 1 | 1 | Yes | No |
| 16959094 | USE OF MEVALONATE METABOLIC PATHWAY INHIBITOR AND ALPHAVIRUS IN PREPARING ANTI-TUMOR DRUG | September 2020 | May 2024 | Abandon | 46 | 0 | 1 | No | No |
| 16996237 | COUPLED REDIRECTED CELLS AND USES THEREOF | August 2020 | December 2024 | Abandon | 52 | 3 | 1 | Yes | No |
| 16956926 | Adeno-Associated Virus (AAV) Vector Having Hybrid HGF Gene Introduced Thereto | June 2020 | February 2023 | Allow | 31 | 1 | 0 | Yes | No |
| 16905274 | MATERIAL DEPOSITING SYSTEM FOR TREATING A PATIENT | June 2020 | October 2024 | Abandon | 52 | 2 | 1 | No | No |
| 16772033 | RECOMBINANT ADENOVIRUSES AND STEM CELLS COMPRISING SAME | June 2020 | August 2023 | Allow | 38 | 1 | 1 | Yes | No |
| 16763957 | Non-human papillomaviruses for gene delivery in vitro and in vivo | May 2020 | August 2023 | Allow | 39 | 1 | 1 | No | No |
| 16814120 | Methods for Transfecting Nucleic Acid Into Live Cells | March 2020 | May 2024 | Abandon | 50 | 2 | 0 | No | No |
| 16751008 | METHOD OF MANUFACTURING CELL SPHEROID USING BIOINK | January 2020 | September 2023 | Allow | 43 | 2 | 0 | Yes | No |
| 16491219 | METHOD FOR PRODUCING PLATELETS | January 2020 | November 2023 | Allow | 51 | 2 | 1 | Yes | No |
| 16717577 | LIPOSOME COMPOSITIONS AND METHODS OF USE THEREOF | December 2019 | August 2023 | Allow | 43 | 1 | 1 | No | No |
| 16621823 | MULTIGENE CONSTRUCT FOR IMMUNE-MODULATORY PROTEIN EXPRESSION AND METHODS OF USE | December 2019 | August 2023 | Abandon | 44 | 1 | 1 | No | No |
| 16620412 | HUMAN FATTY-LIVER MODEL CELLS | December 2019 | May 2025 | Abandon | 60 | 5 | 1 | Yes | No |
| 16701917 | Modified Cell with Enhanced Migration Capability | December 2019 | December 2023 | Allow | 48 | 2 | 1 | Yes | No |
| 16691812 | GAMMA DELTA T CELLS AND USES THEREOF | November 2019 | April 2025 | Abandon | 60 | 3 | 1 | No | No |
| 16686910 | RECOMBINANT ADIPOSE-DERIVED STEM CELL EXPRESSING BDDHFVIII GENE, AND PREPARATION METHOD AND APPLICATION THEREOF | November 2019 | March 2024 | Abandon | 52 | 2 | 1 | No | No |
| 16486905 | A GANGLIOGLIOMA-INDUCED ANIMAL MODEL AND A METHOD FOR DIAGNOSING AND TREATING GANGLIOGLIOMA AND RELATED DISEASES | August 2019 | March 2025 | Allow | 60 | 4 | 1 | Yes | No |
| 16302581 | Anabolic Enhancers for Ameliorating Neurodegeneration | November 2018 | January 2025 | Abandon | 60 | 5 | 1 | No | No |
| 16023010 | METHOD OF MEASURING ADAPTIVE IMMUNITY | June 2018 | October 2023 | Allow | 60 | 3 | 1 | No | No |
| 15941409 | GENERATION OF THERAPEUTIC CELLS USING EXTRACELLULAR COMPONENTS OF TARGET ORGANS | March 2018 | January 2023 | Allow | 57 | 3 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner GONZALES, JOSEPHINE MARIA.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner GONZALES, JOSEPHINE MARIA works in Art Unit 1631 and has examined 45 patent applications in our dataset. With an allowance rate of 37.8%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 43 months.
Examiner GONZALES, JOSEPHINE MARIA's allowance rate of 37.8% places them in the 3% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by GONZALES, JOSEPHINE MARIA receive 1.73 office actions before reaching final disposition. This places the examiner in the 51% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by GONZALES, JOSEPHINE MARIA is 43 months. This places the examiner in the 3% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +48.1% benefit to allowance rate for applications examined by GONZALES, JOSEPHINE MARIA. This interview benefit is in the 93% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 20.0% of applications are subsequently allowed. This success rate is in the 13% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 28.6% of cases where such amendments are filed. This entry rate is in the 32% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants file petitions regarding this examiner's actions, 88.9% are granted (fully or in part). This grant rate is in the 94% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.